Premium
Bisphosphonate Space Measurement in Paget's Disease of Bone Treated with APD
Author(s) -
Stone M. D.,
Marshall D. H.,
Hosking D. J.,
Perkins A. C.,
Evans A. J.,
Wastie M. L.
Publication year - 1992
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.5650070308
Subject(s) - bisphosphonate , medicine , bone density conservation agents , bone disease , paget disease , disease , dentistry , osteoporosis , bone density
Abstract The bisphosphonate space (BPS) is a quantitative measurement of skeletal uptake of 99m Tc‐HMDP. We measured BPS in 36 patients with Paget's disease of bone, both before and 6 months after treatment with intravenous APD (disodium pamidronate) infusions. BPS fell after treatment, but proportionally less than serum alkaline phosphatase (ALP) and fasting urinary hydroxyproline/creatinine (HYPRO). There was no dose‐response relationship between the dose of APD given and the percentage reduction in ALP and HYPRO at 6 months. Log dose of APD/pretreatment BPS, however, predicted the percentage reduction in ALP and HYPRO very well, and from the respective regression equations it was possible to predict the dose of APD needed to achieve normal values of ALP and HYPRO. In the 10 patients who achieved a normal ALP and 9 patients a normal HYPRO after more than 6 months treatment with APD (range 7–18 months), the predicted dose of APD agreed closely with the actual dose. In conclusion, our data support the idea that log dose APD/pretreatment BPS is a valid predictor of biochemical response in Paget's disease.